Daratumumab, bortezomib, cyclophosphamide and dexamethasone in newly diagnosed and relapsed multiple myeloma: LYRA study

This United States community study evaluated the combination of daratumumab, bortezomib, cyclophosphamide and dexamethasone (D‐VCd) in newly diagnosed multiple myeloma (NDMM) and relapsed multiple myeloma (RMM). Patients received 4–8 induction cycles of bortezomib 1·5 mg/m(2), cyclophosphamide 300 m...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Br J Haematol
Main Authors: Yimer, Habte, Melear, Jason, Faber, Edward, Bensinger, William I., Burke, John M., Narang, Mohit, Stevens, Don, Gunawardena, Sriya, Lutska, Yana, Qi, Keqin, Ukropec, Jon, Qi, Ming, Lin, Thomas S., Rifkin, Robert M.
Formato: Artigo
Idioma:Inglês
Publicado: John Wiley and Sons Inc. 2019
Assuntos:
Haematological Malignancy
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6593455/
https://ncbi.nlm.nih.gov/pubmed/30828799
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bjh.15806
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares